Business conference presentation

Innate Pharma to Present at AACR Event

Analysis based on 7 articles · First reported Apr 08, 2026 · Last updated Apr 08, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

This event is expected to have a positive, albeit minor, impact on the biotechnology sector, particularly for Innate Pharma. The presentation at the AACR Oncology Industry Partnering Event could increase investor awareness and potentially lead to new partnerships or investments for Innate Pharma, positively influencing its stock performance.

Biotechnology Pharmaceuticals

Event Summary

Innate Pharma announced that its Chief Operating Officer, Yannis Morel, will present at the AACR Oncology Industry Partnering Event on April 16, 2026, in San Diego, California. This event is a key forum for biotech and pharmaceutical leaders, venture capitalists, and investors focused on oncology drug development. Innate Pharma's selection to present highlights its clinical pipeline, including assets like IPH4502, lacutamab, and monalizumab, and offers a valuable opportunity to share progress and potentially accelerate the development of its differentiated therapies for cancer patients. The company aims to spark conversations and interactions that could lead to further investment and collaboration.

Key Actions

90 Innate Pharma selected to present at industry partnering event American Association for Cancer Research

85 Yannis Morel to present company's oncology pipeline

Entities Involved

stock

Innate Pharma

Innate Pharma will present its oncology pipeline, platforms, and strategies for innovation at the AACR Oncology Industry Partnering Event, providing a valuable opportunity to share progress on key assets like IPH4502. This presentation could attract investor interest and potentially accelerate the development of its therapies.

Importance 100 Sentiment 20

per

Yannis Morel

Yannis Morel, Chief Operating Officer of Innate Pharma, will be the presenter at the AACR Oncology Industry Partnering Event, highlighting the company's clinical pipeline. His role as presenter is crucial for communicating Innate Pharma's advancements to investors and analysts.

Importance 70 Sentiment 10

ngo

American Association for Cancer Research

The American Association for Cancer Research (AACR) is hosting the Oncology Industry Partnering Event, which serves as a significant forum for biotechnology and pharmaceutical leaders, venture capitalists, and investment bankers. This event provides a platform for companies like Innate Pharma to showcase their oncology drug development.

Importance 60 Sentiment 0

stock

Sanofi

Sanofi is mentioned as a collaborator with Innate Pharma, indicating existing partnerships in immuno-oncology. While not directly involved in this specific presentation, its association with Innate Pharma highlights the latter's credibility.

Importance 10 Sentiment 0

stock

AstraZeneca

AstraZeneca is noted as a collaborator with Innate Pharma on the anti-NKG2A antibody monalizumab for non-small cell lung cancer. This collaboration underscores Innate Pharma's strategic alliances within the pharmaceutical industry.

Importance 10 Sentiment 0

Relationships

Innate Pharma related ↔ Sanofi

Innate Pharma related ↔ AstraZeneca

Yannis Morel related ↔ Innate Pharma

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard